Esperion Therapeutics, Inc., was incorporated in Delaware in January 2008. The Company is a late-stage pharmaceutical company focused on developing and commercializing complementary, convenient, cost-effective once-daily oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence and a deep understanding of cholesterol biology, the company's experienced lipid management team is committed to developing new LDL-C lowering therapies that will have a significant impact on reducing global cardiovascular disease or cardiovascular disease; a leading cause of death worldwide.
